Life Sciences

JUNE 23, 2020

In this Pullan's Pieces webinar, the third in the series, business development consultant, Linda Pullan, PhD, will present an overview of the inflammation therapeutics landscape. This will include snapshots of diseases, unmet needs...

JAN 2020

Cancer is the biggest therapeutic area for licensing deals. But there are almost 3,000 drugs in Phase 1 through Phase 3, so competition for licensing deals and for market position is huge. Checkpoint inhibitors have...

APRIL 2020

Life science founders are technical experts in their fields, but frequently fail to understand the needs of the stakeholders who will determine their path to market. This gap sends investors running, and all but ensure...

MAY 2020

Life sciences companies are increasingly providing treatment-related items and services to support patients, such as nebulizers, utilization tracking tools and home health visits. Proactive engagement strategies...

NOV 2019

Just 7 years since Novartis paid UPenn $20M to access Carl June’s anti-CD19 CAR-T technology, the field of adoptive cell therapy (ACT) in cancer has expanded dramatically, both in investment activity and technology proliferation...

OCT 2019

Interest in investing in healthcare services and technology companies is at unprecedented levels. Supported by enormous reserves of capital, large companies, private equity firms, and family offices are buying medical groups...

APRIL 2020

Life science founders are technical experts in their fields, but frequently fail to understand the needs of the stakeholders who will determine their path to market. This gap sends investors running...

FEB 2020

Cancer is the biggest therapeutic area for licensing deals. But there are almost 3,000 drugs in Phase 1 through Phase 3, so competition for licensing deals and for market position is huge. Checkpoint inhibitors...

DEC 2019

Interest in investing in healthcare services and technology companies is at unprecedented levels. Supported by enormous reserves of capital, large companies, private equity firms, and family offices are buying medical...

November 2019

While ACTs have yet to score any major wins in solid tumors beyond the early success of TILs, many early-stage clinical programs are slated to readout within the next few years.

In this discussion, we asked a panel of experts their views on the most exciting new developments, what they seek to license...

June 2019

The human body and its microbiome live in a symbiotic relationship In this webinar, biopharma partnering expert and Life Sciences consultant, Linda Pullan, PhD, explores today’s oncology landscape and offered her perspective on trends, pipeline by indication, dealmaking, and the top ten...

Based on the web panel discussion on January 2019

Antibody-Drug Conjugates (ADC) combine the specificity of the antibody recognizing the antigen target, typically with the potent tumor-killing effects of a cytotoxic, attached typically via a linker to the antibody. Six ADCs have already been approved; sales are expected to be about $2b in 2018, growing to $12b by...

January 2019

Antibody-Drug Conjugates (ADC) combine the specificity of the antibody recognizing the antigen target, typically with the potent tumor-killing effects of a cytotoxic, attached typically via a linker to the antibody. Six ADCs have already been approved; sales are expected to be about $2b in 2018, growing to $12b by... 

December 2018

Precision medicine, which has been pioneered by the field of oncology, aims to target the right treatments to the right patients at the right time. Recent advances in genomics and imaging, as well as the discovery of other biomarkers, have enabled...

It’s not easy to go from a nascent scientific concept to a fully-funded life sciences organization. In this web panel discussion, the panelists discussed the best ways to navigate this path successfully. The discussion provided examples of how executive teams can partner business...

The clinical trial industry is highly regulated with a complex landscape. Contract Research Organizations (CROs) are a big part of any strategic product development life cycle. Sponsoring companies of new drugs, devices or biologics may outsource all or part of their clinical research.

August 2018

The clinical trial industry is highly regulated with a complex landscape. Contract Research Organizations (CROs) are a big part of any strategic product development life cycle. Sponsoring companies of new drugs, devices or biologics may outsource all or part of their clinical research...